ALMIRALL, S.A. «...678910...» Page 10 out of 16 15/11/2021 06:55 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the third quarter of 2021. Register number: 12747 01/11/2021 08:01 ALMIRALL, S.A. Other relevant information AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma. Register number: 12510 05/10/2021 17:32 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el tercer trimestre de 2021 Register number: 12065 22/09/2021 12:41 ALMIRALL, S.A. On financial instruments Almirall, S.A. of its 2.125 % senior notes in an aggregate principal amount of €300,000,000 due 2026 has successfully been closed and paid Register number: 11778 15/09/2021 18:05 ALMIRALL, S.A. On financial instruments Almirall has successfully completed the pricing of the issuance of senior notes in an aggregate principal amount of €300 million due 2026 Register number: 11684 Related to communication no. 11601 dated 13/09/2021 (08:39) 13/09/2021 08:39 ALMIRALL, S.A. On financial instruments Almirall, S.A. has decided to carry out an issuance of senior notes in an aggregate maximum principal amount of €250,000,000 due 2026 Register number: 11601 16/08/2021 07:54 ALMIRALL, S.A. On business and financial situation Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials Register number: 11305 26/07/2021 06:56 ALMIRALL, S.A. On corporate governance Comisión de Dermatología & Comisión de Nombramientos y Retribuciones Register number: 10795 26/07/2021 06:47 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2021 Register number: 10794 26/07/2021 06:45 ALMIRALL, S.A. On business and financial situation First semester results presentation 2021 Register number: 10793 Page 10 out of 16 «...678910...»